From The Industry Experts

  1. 5 Signals Teams Should Track To Avoid Clinical Trial Execution Drift 6/4/2026

    Many teams detect execution drift too late. To stay head, learn how to follow these five governance signals: documentation reliability, ownership clarity, dependency visibility, escalation discipline, and decision-ready review quality.

  2. What Is Ontology? Learn About The Data Layer That Makes Agentic AI Work 6/3/2026

     Get an overview of ontology, the "semantic translator" that determines whether your AI investments actually compound or stay forever siloed.

  3. Building A Scalable Oncology Engine In A Dynamic Market 6/3/2026

    Learn how a top-10 global pharmaceutical company partnered with Medable to rapidly scale the number of oncology trials it could concurrently conduct.

  4. The New Blueprint For Oncology Trials: Agility, Consistency, & Scale 6/3/2026

    Oncology trials are increasingly complex, exposing gaps in traditional operations; consistency, scalability, and agility help teams adapt faster and reduce inefficiencies.

  5. Lessons In Pivoting From A Clinical Trial Launch In Uganda 6/3/2026

    Gates MRI researchers share how they navigated supply chain challenges, an Ebola outbreak, and evolving regional malaria vaccination strategies to successfully execute a malaria clinical trial in Uganda.

  6. DDW 2026 Signalled The Next Era Of Competitive Landscape In IBD 6/2/2026

    At the DDW 2026 meeting, the IBD landscape was portrayed as increasingly competitive and diversified, with emerging players and novel mechanisms challenging established standards of care.

  7. What Is Computer Software Assurance, And What Are Its Benefits? 6/2/2026

    Kamila Novak reviews final computer software assurance (CSA) guidance and what it means for those working on medical device clinical trials.

  8. The FDA Is Rudderless And Clinical Trials Are Left Adrift 6/2/2026

    Former commissioner Marty Makary, MD, left the FDA in May 2026. In his wake, he left an agency facing yet another wave of uncertainty. Denise N. Bronner attempts to navigate the latest change and offers advice for those seeking stability.

  9. Expanding Access To Cell Therapy Trials Beyond AMCs And Into The Community 6/1/2026

    CEO Paul J. Hastings discusses Nkarta's decision to bring outpatient dosing into the community setting, including how it communicated with the FDA on safety and how the changes will improve patient access. 

  10. What's The Role Of HEOR For A Clinical Researcher? A Perspective From ISPOR 2026 6/1/2026

    On the heels of ISPOR 2026, discover what relevancy HEOR has in the world of clinical operations.